世界のオリゴヌクレオチド合成市場：オリゴ合成装置、試薬、サービス...市場調査レポートについてご紹介

TABLE OF CONTENTS

1 INTRODUCTION 17
1.1 OBJECTIVES OF THE STUDY 17
1.2 MARKETS COVERED 17
1.3 STAKEHOLDERS 18
1.4 MARKET SCOPE 19
2 RESEARCH METHODOLOGY 20
2.1 MARKET SIZE ESTIMATION 21
2.2 MARKET CRACKDOWN & DATA TRIANGULATION 23
2.3 KEY DATA FROM SECONDARY SOURCES 23
2.4 KEY DATA FROM PRIMARY SOURCES 24
2.5 KEY INDUSTRY INSIGHTS 25
2.6 ASSUMPTIONS 25
3 EXECUTIVE SUMMARY 26
4 PREMIUM INSIGHTS 29
4.1 ATTRACTIVE MARKET OPPORTUNITIES IN THE SYNTHESIZED OLIGONUCLEOTIDES MARKET 29
4.2 OLIGONUCLEOTIDE SYNTHESIS MARKET IN THE ASIA-PACIFIC REGION 30
4.3 U.S. COMMANDS NEARLY HALF OF THE MARKET SHARE 31
4.4 GEOGRAPHIC REVIEW OF THE OLIGONUCLEOTIDE SYNTHESIS MARKET 32
4.5 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET: PCR SEGMENT (2019) 33
4.6 SIGNIFICANT CONTRIBUTION OF SYNTHESIZED OLIGONUCLEOTIDES TO THE TOTAL MARKET GROWTH FROM 2014–2019 34
4.7 LIFE CYCLE ANALYSIS, BY GEOGRAPHY 35
5 MARKET OVERVIEW 36
5.1 INTRODUCTION 37
5.2 MARKET SEGMENTATION 37
5.2.1 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCTS & SERVICES 37
5.2.2 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION 38
5.2.3 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER 38
5.3 MARKET DYNAMICS 39
5.3.1 DRIVERS 40
5.3.1.1 Increasing R&D expenditure in pharmaceutical and biotechnology companies to boost the synthetic oligonucleotides (oligos) market 40
5.3.1.2 Rising demand from researchers owing to the growing molecular biology field is driving the market growth 40
5.3.1.3 Increasing significance of personalized medicine, companion diagnostics, and molecular diagnostics driving the market growth 40
5.3.1.4 Continuous innovations in genomics technologies & presence of favorable government support to boost market growth 41
5.3.1.5 Increasing demand for synthetic genes is propelling the demand for oligos 41
5.3.2 RESTRAINTS 43
5.3.2.1 Continuous downward price pressure posing as a major market growth barrier 43
5.3.2.2 Regulatory challenges opposing the market growth, especially for therapeutic oligos 43
5.3.3 OPPORTUNITIES 44
5.3.3.1 Asian market presents significant growth opportunities 44
5.3.3.2 Emerging field of NGS to boost demand for NGS-grade oligos 44
5.3.4 CHALLENGES 46
5.3.4.1 Large-scale synthesis of oligonucleotides 46
5.3.4.2 Manufacturing high-quality RNA oligos 46
5.4 LEADING MARKET PLAYERS 47
5.4.1 EQUIPMENT MARKET 47
5.4.2 REAGENTS MARKET 47
5.4.3 SYNTHESIZED OLIGONUCLEOTIDES MARKET 48
6 INDUSTRY TRENDS 50
6.1 INTRODUCTION 50
6.1.1 INDUSTRY TRENDS 50
6.2 PORTER’S FIVE FORCES ANALYSIS 51
6.2.1 THREAT FROM NEW ENTRANTS 52
6.2.2 THREAT FROM SUBSTITUTES 52
6.2.3 BARGAINING POWER OF SUPPLIERS 52
6.2.4 BARGAINING POWER OF BUYERS 52
6.2.5 INTENSITY OF COMPETITIVE RIVALRY 53
6.3 PEST ANALYSIS 53
6.3.1 POLITICAL FACTORS 54
6.3.2 ECONOMIC FACTORS 54
6.3.3 SOCIAL FACTORS 54
6.3.4 TECHNOLOGICAL FACTORS 55
6.4 SUPPLY CHAIN ANALYSIS 55
6.4.1 KEY INFLUENCERS 56
7 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCTS & SERVICES 57
7.1 INTRODUCTION 58
7.2 SYNTHESIZED OLIGONUCLEOTIDES 60
7.2.1 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT 61
7.2.1.1 Primers 62
7.2.1.2 Probes 63
7.2.1.3 Large-scale Synthesis Oligos 64
7.2.1.4 Intermediate-scale Synthesis Oligos 65
7.2.2 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY SERVICE 66
7.2.2.1 Custom Oligos 67
7.2.2.2 Predesigned Oligos 68
7.3 REAGENTS 69
7.4 EQUIPMENT 71
8 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION 74
8.1 INTRODUCTION 75
8.2 RESEARCH 76
8.2.1 PCR 78
8.2.2 QPCR 79
8.2.3 SEQUENCING 80
8.2.4 GENE SYNTHESIS 81
8.2.5 OTHER RESEARCH APPLICATIONS 83
8.3 DIAGNOSTICS 84
8.4 THERAPEUTICS 85
8.4.1 DNA/ANTISENSE OLIGOS 87
8.4.2 RNAI 88
8.4.3 NUCLEIC ACID APTAMERS 89
8.4.4 OTHER THERAPEUTIC APPLICATIONS 89
9 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER 91
9.1 INTRODUCTION 92
9.2 ACADEMIC RESEARCH INSTITUTES 93
9.3 DIAGNOSTIC LABORATORIES 95
9.4 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 96
9.5 OTHERS 97
10 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, BY GEOGRAPHY 98
10.1 INTRODUCTION 99
10.2 NORTH AMERICA 100
10.2.1 U.S. 105
10.2.2 CANADA 106
10.3 EUROPE 107
10.4 ASIA-PACIFIC (APAC) 110
10.5 LATIN AMERICA 116
10.6 MIDDLE EAST & AFRICA 119
11 COMPETITIVE LANDSCAPE 123
11.1 OVERVIEW 123
11.2 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS, CONTRACTS, & JOINT VENTURES 126
11.3 EXPANSIONS 127
11.4 NEW PRODUCT LAUNCHES 128
11.5 MERGERS & ACQUISITIONS 129
11.6 OTHER DEVELOPMENTS 130
12 COMPANY PROFILES 131
12.1 BIOAUTOMATION CORPORATION 131
12.2 GE HEALTHCARE (A SUBSIDIARY OF GENERAL ELECTRIC COMPANY) 134
12.3 INTEGRATED DNA TECHNOLOGIES 137
12.4 SIGMA-ALDRICH CORPORATION 142
12.5 THERMO FISHER SCIENTIFIC, INC. 148
12.6 BIOSEARCH TECHNOLOGIES, INC. 154
12.7 EUROFINS GENOMICS (A SUBSIDIARY OF EUROFINS SCIENTIFIC GROUP) 158
12.8 EUROGENTEC (A SUBSIDIARY OF KANEKA CORPORATION) 161
12.9 GENEDESIGN, INC. 164
12.10 TRILINK BIOTECHNOLOGIES, INC. 166
*Details on Business Overview, Financial, Product Portfolio, Key Strategy, & Recent Developments might not be captured in case of unlisted companies.
13 APPENDIX 169
13.1 DISCUSSION GUIDE 169
13.2 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 172
13.3 AVAILABLE CUSTOMIZATIONS 173
13.4 RELATED REPORTS 174